A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease

Brian G. Feagan*, Richard N. Fedorak, E. Jan Irvine, Gary Wild, Lloyd Sutherland, A. Hillary Steinhart, Gordon R. Greenberg, John Koval, Cindy J. Wong, Marybeth Hopkins, Stephen B. Hanauer, John W D Mcdonald

*Corresponding author for this work

Research output: Contribution to journalArticle

609 Scopus citations

Abstract

Background: Patients with Crohn's disease often have relapses. Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known. Methods: We conducted a double-blind, placebo-controlled, multicenter study of patients with chronically active Crohn's disease who had entered remission after 16 to 24 weeks of treatment with 25 mg of methotrexate given intramuscularly once weekly. Patients were randomly assigned to receive either methotrexate at a dose of 15 mg intramuscularly once weekly or placebo for 40 weeks. No other treatments for Crohn's disease were permitted. We compared the efficacy of treatment by analyzing the proportion of patients who remained in remission at week 40. Remission was defined as a score of 150 or less on the Crohn's Disease Activity Index. Results: Forty patients received methotrexate, and 36 received placebo. At week 40, 26 patients (65 percent) were in remission in the methotrexate group, as compared with 14 (39 percent) in the placebo group (P=0.04; absolute reduction the risk of relapse, 26.1 percent; 95 percent confidence interval, 4.4 percent to 47.8 percent). Fewer patients in the methotrexate group than in the placebo group required prednisone for relapse (11 of 40 [28 percent] vs. 21 of 36 [58 percent], P=0.01). None of the patients who received methotrexate had a severe adverse event; one patient in this group withdrew because of nausea. Conclusions: In patients with Crohn's disease who enter remission after treatment with methotrexate, a low dose of methotrexate maintains remission.

Original languageEnglish (US)
Pages (from-to)1627-1632
Number of pages6
JournalNew England Journal of Medicine
Volume342
Issue number22
DOIs
StatePublished - Jun 1 2000

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease'. Together they form a unique fingerprint.

  • Cite this

    Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., Hanauer, S. B., & Mcdonald, J. W. D. (2000). A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. New England Journal of Medicine, 342(22), 1627-1632. https://doi.org/10.1056/NEJM200006013422202